tm
Seeing Is Believing
tm
Seeing Is Believing
Healthcare - Sector
BIIB is currently covered by 27 analysts with an average price target of $228.24. This is a potential downside of $12.74 (-5.29%) from yesterday's end of day stock price of $240.98.
Biogen's activity chart (see below) currently has 1,203 price targets and 931 ratings on display. The stock rating distribution of BIIB is 47.25% BUY, 50.55% HOLD and 2.2% SELL.
Analysts average stock forecasts to be materialized ratio is 61.07% with an average time for these price targets to be met of 209.29 days.
Highest price target for BIIB is $310, Lowest price target is $150, average price target is $228.24.
Most recent stock forecast was given by PHIL NADEAU from TD COWEN. First documented stock forecast 09-Sep-2010.
Biogen is focused on the discovery, development, manufacturing innovative therapies for the treatment of neurological and neurodegenerative diseases.
Biogen offers a diverse portfolio of therapies targeting various neurological conditions.
For multiple sclerosis (MS), the company provides products such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA, which aim to manage and alleviate the symptoms of this chronic autoimmune disease.
Biogen’s SPINRAZA is a groundbreaking therapy for spinal muscular atrophy (SMA), a genetic neuromuscular disorder that affects muscle movement. The company’s innovative treatment, ADUHELM, addresses Alzheimer’s disease, a progressive neurodegenerative disorder characterized by cognitive decline.
In addition to MS, SMA, and Alzheimer’s disease, Biogen’s product lineup encompasses various therapeutic areas. The company offers FUMADERM to treat plaque psoriasis, a chronic skin condition. BENEPALI, IMRALDI, and FLIXABI are biosimilars developed by Biogen, referencing well-established therapies for conditions like rheumatoid arthritis and certain types of cancer.
Furthermore, Biogen delivers therapies like RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and glofitamab to address a range of disorders, including non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, and other immunological and neurovascular conditions.
Biogen’s headquarters are located in Cambridge, Massachusetts, since it was founded in 1978.
Currently out of the existing stock ratings of BIIB, 43 are a BUY (47.25%), 46 are a HOLD (50.55%), 2 are a SELL (2.2%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 20-Oct-2021
$250
$9.02 (3.74%)
$225
Buy Since 20-Oct-2026
$310
$69.02 (28.64%)
$250
Hold Since 30-Sep-2022
$300
$59.02 (24.49%)
$185
10 days ago
(12-Oct-2026)
7/8 (87.5%)
$74.29 (32.91%)
329
Buy Since 17-May-2026
$270
$29.02 (12.04%)
$240
13 days ago
(09-Oct-2026)
15/41 (36.59%)
$44.29 (19.62%)
175
Buy Since 04-May-2022
$256
$15.02 (6.23%)
$260
14 days ago
(08-Oct-2026)
59/88 (67.05%)
$37.57 (17.20%)
179
What is BIIB (Biogen) average time for price targets to be met?
Which analyst most recently updated their price target on BIIB (Biogen)?
Which analyst has the most public recommendations on BIIB (Biogen)?
Which analyst is the currently most bullish on BIIB (Biogen)?
Which analyst is the currently most reserved on BIIB (Biogen)?
